

Public Reporting burden of this collection of information is estimated at 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton Road NW, MS D-74, Atlanta, GA 30333; Attn: PRA (0920-XXXX).

**Interview Guide PDO/naloxone partners and stakeholders**

Hello, this is \_\_\_\_\_ with Battelle. Thank you for agreeing to participate in today's interview. Battelle is a research organization and we are working with CDC and SAMHSA to conduct an evaluation of the SAMHSA-funded grants to Prevent Prescription Drug/Opioid Overdose-Related Deaths, or the PDO/Naloxone grant. The evaluation is intended to help understand the scope and impact of the program on overdose fatalities, increase our understanding of program effectiveness, and increase understanding of barriers and facilitators to program implementation. You have been asked to participate in an interview because you are involved in this work and we are interested in learning about your perspective and experiences with the PDO/naloxone grant.

If you agree to participate in the interview, we will ask you a series of questions related to the PDO/naloxone activities that are occurring in your jurisdiction. This interview will take about 60 minutes or less of your time. Your participation is completely voluntary. You can decide whether or not to participate. If you do agree to participate, you may stop at any time. You may also choose to not answer any questions. Should you choose to participate, your answers will be maintained in a secure manner and you will not be identified by name or description in any reports.

Do you have any questions for me?

Are you willing to participate in the interview?

We would also like to audio tape the interview for transcribing purposes only. You will not be identified by name or description in any of the audio recordings. Once the interviews have been transcribed, the tapes will be erased.

Are you willing to have the interview audio taped?

***[Begin recording]***

1. First, please tell us about your role with the PDO/naloxone grant?  
Probe: when did you first get involved?

Probe: did you experience any challenges when first getting involved? If so, how were these addressed?

2. Are you involved in providing Naloxone education and/or training?

*[If yes continue; if no then skip to Q7:]*

3. Please describe how naloxone education and training is being provided? (In subsequent years can ask about whether there have been any changes)  
(Probe: How does education and training vary by audience?)
4. What approaches do you think work best when providing naloxone education and training? Which approaches are least effective?
5. What factors facilitate the process of providing education and training to various audiences?
6. What factors were barriers or challenges to providing training and education?  
Probe: How did you address these?
7. Are you involved in distributing naloxone?

*[If yes continue; if no, skip to Q10:]*

8. Can you briefly describe how naloxone is being distributed?  
Probe: If distributed directly to communities, ask about that. If distributed to partners, ask about that.
9. Tell me about the factors that facilitate distribution of naloxone? What factors impede distribution or were challenging?
10. Have you been trained to administer naloxone?

*[If yes continue; if no, skip to Q14:]*

11. Please describe how you were trained to administer naloxone?  
Probe: Who provided the training?
12. Thinking about when you were trained, what aspects of the training were most effective? Least effective?
13. What aspects of the training could be improved upon?

**Partnerships and Collaboration [Ask as relevant based on individual's role]**

14. How do you collaborate and/or work with partners as part of your naloxone work?  
Probe: To provide education/training?  
Probe: To distribute/increase access to naloxone?
15. What have you seen as the benefits of these collaborations and partnerships?
16. What challenges were encountered when working in these partnerships and how were they addressed?

**Disparities [Ask as relevant based on individual's role]**

17. What approaches does your organization use to address disparities in your PDO/naloxone work?  
Probe: What approaches were most successful and why?  
Probe: What approaches didn't seem to work and why?  
Probe: Which populations were reached by your efforts?

**Policies**

18. What impact does state or local support for naloxone have on access and availability of naloxone in your community?  
Probe: What impact does state/local policies/laws have?  
Probe: Which particular state/local policies or laws impact this?

**Other [Asked as relevant based on individual's role]**

19. When thinking about any systems your organization developed or uses for tracking and monitoring data related to the PDO/naloxone grant, what works well? What aspects do not work as well or could be improved?
20. How has the PDO/naloxone funding helped develop or increase distribution infrastructure to reduce the number of prescription drug/opioid overdose-related deaths and adverse events?
21. What would you consider key accomplishments of your program or partners' work on the PDO naloxone grant?

**Year 3 and 4 Questions [Questions to be asked during later rounds of data collection]**

22. When thinking about the work you are doing related to the PDO/naloxone grant, what factors facilitate program implementation? What factors impede program implementation?
23. What program elements were most successful? Why?

24. What program elements were least successful? Why?
25. Do you think the changes that have been created in your community as a result of this grant will be sustained after the funding? How will changes be sustained?
26. In what ways do you think support for naloxone has changed during the funding period?
27. Is there anything else you think is important to our evaluation that you'd like to share?

**Conclusion**

Thank you so much for your time today. Your input will help us better understand how the PDO/naloxone grant funding is being used in your community. What we learn from this will help other communities in the future as well. So, again, thank you.